Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21

Vaccine

Volumn 20, Issue 17-18, 2002, Pages 2263-2277

  Kashala, Oscar ^a,d   Amador, Roberto ^b   Valero, Maria V ^b   Moreno, Alberto ^b   Barbosa, Arnoldo ^a,b   Nickel, Beatrice ^c   Daubenberger, Claudia A ^c   Guzman, Fanny ^b   Pluschke, Gerd ^c   Patarroyo, Manuel E ^b  

^a Aquila Biopharmaceuticals Inc   (United States)

^b FUNDACIÓN INSTITUTO DE INMUNOLOGÍA DE COLOMBIA FIDIC   (Colombia)

^c SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^d EMD Pharmaceuticals Inc   (United States)

Author keywords

Clinical trial; Malaria peptide vaccine; QS 21

Indexed keywords

ALUMINUM HYDROXIDE; ANTIBODY; CD4 ANTIGEN; CD8 ANTIGEN; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; MALARIA VACCINE; QS 21;

ADULT; ALLERGIC REACTION; ANGIONEUROTIC EDEMA; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BRONCHOSPASM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG FORMULATION; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEVER; HEADACHE; HUMAN; HYPOTENSION; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOGENICITY; INFLAMMATION; MAJOR CLINICAL STUDY; MALAISE; MALARIA FALCIPARUM; MALE; PAIN; PHASE 1 CLINICAL TRIAL; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; T LYMPHOCYTE; VACCINE PRODUCTION;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANIMALS; CHEMISTRY, PHARMACEUTICAL; CONSUMER PRODUCT SAFETY; DOUBLE-BLIND METHOD; DRUG TOLERANCE; HUMANS; MALARIA VACCINES; MALARIA, FALCIPARUM; MALE; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; RECOMBINANT PROTEINS; SAPONINS; VACCINES, SYNTHETIC;

EID: 0037157260     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00115-9     Document Type: Article

References (41)

1. World Malaria Situation in 1994. Part II
2. Malaria vaccine development: Current status
3. Induction of protective immunity against experimental infection with malaria using synthetic peptides
4. A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum
5. Safety and immunogenicity of the synthetic peptide malaria vaccine SPf66 in a large field trial
6. The first field trials of the chemically-synthesised malaria vaccine SPf66: Safety, immunogenicity and protectivity
7. Vaccination with SPf66, a chemically synthesised vaccine, against Plasmodium falciparum malaria in Colombia
8. Safety, immunogenicity and protective effect of the SPf66 malaria synthetic vaccine against Plasmodium falciparum infection in randomised double-blind placebo-controlled field trial in an endemic area of Ecuador
9. A population-based clinical trial with the SPf66 synthetic Plasmodium falciparum Malaria vaccine in Venezuela
10. SPf66, a chemically synthesised subunit malaria vaccine is safe and immunogenic in Tanzanians exposed to malaria transmission
11. Randomised trial of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania
12. Evaluation of the SPf66 vaccine for malaria control when delivered through the EPI scheme in Tanzania
13. Efficacy trial of malaria vaccine SPf66 in Gambian infants
14. Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand
15. Evaluation of SPf66 malaria vaccine efficacy in Brazil
16. Phase I safety and immunogenicity testing of chemical lots of the synthetic Plasmodium falciparum vaccine SPf66 produced under good manufacturing procedure conditions in the United States
17. The SPf66 malaria vaccine: What is the evidence for efficacy?
18. Analysis of multiple Plasmodium falciparum infections in Tanzanian children during the phase III trial of the malaria vaccine SPf66
19. Reduction in the mean number of Plasmodium falciparum genotypes in Gambian children immunized with the malaria vaccine SPf66
20. Immune responses to Plasmodium falciparum antigens during a malaria vaccine trial in Tanzanian children
21. Separation and characterisation of saponins with adjuvant activity from Quillaja saponaria Molina cortex
22. Saponins as vaccine adjuvants
23. Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma
24. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group
25. Antibody responses in melanoma patients immunised with an anti-idiotype antibody mimicking disialoganglioside GD2
26. QS-21: A water-soluble triterpene glycoside adjuvant
27. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria
28. Synthetic malaria peptide vaccine elicits high levels of antibodies in vaccinees of defined HLA genotypes
29. Studies on the humoral immune response to a synthetic vaccine against Plasmodium falciparum malaria
30. The role of adjuvants and delivery systems in modulation of immune response to vaccines
31. Descriptive epidemiology of adverse events after immunisation: Reports to the vaccine adverse event reporting system (VAERS), 1991-1994
32. Update: Vaccine side effects, adverse reactions, contraindications, and precautions. Recommendations of the Advisory Committee on Immunisation Practices
33. Major adverse reactions to yeast-derived hepatitis B vaccines: A review
34. Two patterns of systemic reactions to Japanese encephalitis vaccines
35. QS-21 is superior to alum as adjuvant with low dose recombinant MN gp120 for immunisation of uninfected adults: Humoral and cellular responses
36. Vaccines against the blood stages of falciparum malaria
37. T-cell control of immunity to the asexual blood stages of the malaria parasite
38. Specific interactions of synthetic peptides derived from P. falciparum merozoite proteins with human red blood cells
39. A rhoptry-associated protein 1-binding monoclonal antibody raised against a heterologous peptide sequence inhibits Plasmodium falciparum growth in vitro